Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-002631-33-DE
EUCTR2008-002631-33-DEActive, not recruitingNot Applicable

Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis - A2209

ovartis Pharma Services AG0 sites60 target enrollmentStarted: August 20, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1.Males or females, aged 18-65 at time of consent.
  • •2.Patients with moderate to severe AS fulfilling the modified NY criteria for a diagnosis of AS and whose disease is not controlled on NSAIDS (on at least one NSAID over a period of at least 3 months at max. dose). Minimum disease activity for inclusion of patients will be assessed based on the ASAS core set domains: back pain & nocturnal pain score = 4 despite concurrent NSAID use, PLUS a BASDAI score = 4. Elevated CRP or ESR are not mandatory for study inclusion.
  • •3.Female subjects must have negative pregnancy test results at screening and baseline.
  • •WoCBP must be using simultaneously double-barrier or two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, hormone contraception as either oral or implantable is acceptable as one form), from the time of screening to 6 months post last dose of AIN457. Women on hormone contraception should be on this regimen for at least 2 months prior to study start.
  • •PM females must have had no regular menstrual bleeding for at least two (2) years prior to initial dosing. If menopause is confirmed by a plasma FSH level of > 40 IU/L at screening, or consistent with menopause per local laboratory, pregnancy test will be required at screening, baseline, before the second infusion and monthly during the study.
  • •Female subjects who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation.
  • •If females have male partners who have undergone vasectomy, the vasectomy must have occurred more than six (6) months prior to first dosing.
  • •Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • •4.Males willing to use simultaneously two acceptable methods of contraception (e.g. spermicidal gel plus condom) for entire duration of the study and at least 6 months post last dose of AIN457.
  • •5.Able to communicate (details in protocol).
  • •6.No evidence of liver disease or liver injury as indicated by abnormal liver function tests such as AST, ALT, ? GGT, AP, or serum bilirubin. The investigator should be guided by criteria as outlined under exclusion criteria
  • •7.Patients with a history of immunization against influenza (within past 12 months) and/or history of pneumococcal vaccination will be included. If not already immunized, vaccination is allowed to be completed (during flu season only) and such patients may be included after a 3-week window post immunization. Immunizations with attenuated life virus should be postponed until after completion of the study.
  • •8.History or presence of PsO or IBD will be recorded.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. WoCBP who are not willing to follow the restrictions in inclusion criteria 3, are not allowed in the study. Men
  • •who are not willing to follow the restrictions in inclusion criteria 4 are not allowed in the study. Male/female
  • •patients who plan to conceive during the time course of the study and
  • •6 months post last infusion of AIN457 are not eligible.
  • •2. Participation in any clinical trial using investigational drug within 4 weeks prior to initial dosing or five half
  • •lives of the IMP, whichever is longer and for any other limitation of participation based on local regulations.
  • •3. For patients who were previously treated with TNF blockers, the washout
  • •periods will be required for these patients to be eligble to participate in the trial.
  • •- 6-month washout period prior to baseline for alefacept.
  • •- 3-month washout period prior to baseline for adalimumab and cerolizumab.
  • •- 2-month washout period for baseline for etanercept or infliximab.
  • •4. a) For patients who were previously treated with immunosuppressive agenst other than methotrexate (MTX),
  • •sulphasalazine (SSZ) and systemic corticosteriods, a 1 month washout period prior to baseline is required.
  • •Immunosuppressive agent include but are not limited to cyclosporine, mycophenolate, trocrolimus and 5-
  • •aminosalicylic acid (5-ASA).
  • •- Prednisone should be kept at a stable dose 4 weeks before baseline and throughout the study and not exceed
  • •- MTX should be kept at a stable dose 4 weeks before baseline and throughout the study and not exceed 25mg/
  • •- SSZ should be kept at a stable dose 4 weeks before baseline and throughout the study.
  • •In case of previous leflunomide treatment, a wash out with oral cholestyramine might be considered as
  • •an alternative wash out procedure to increase the elimination of leflunomide. Based on the notion that
  • •cholestyramine reduces plasma levels of the active leflunomide metabolite by approximately 40% in 24 hours
  • •and by 49% in 48 hours, cholestyramine is to be given orally at a dose of 8 g t.i.d. daily for 10 days. The patient
  • •may then be dosed with study drug not earlier than 2 weeks after start of the cholestyramine wash out procedure.
  • •4. b) Patients who are on NSAIDS should be kept at a stable dose 4 weeks before baseline and throughout the
  • •5. Positive HIV: ELISA and Western blot test result, HBsAg or Hepatitis C test result.
  • •Any active systemic infection within the past 2 weeks including a positive chest X-ray.
  • •6. Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic,
  • •hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral,
  • •psychiatric, chronic inflammatory diseases with the exception of psoriatic arthritis or other disease which in the
  • •clinical judgment of the investigator would make the patient unsuitable for the trial.
  • •7. Liver disease or liver injury as indicated by abnormal liver function tests such as SGOT (AST), SGPT (ALT),
  • •?-GGT, alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the criteria specified in
  • •the protocol.
  • •8. Subjects with active or history of clinically significant cardiac abnormalities as specified in the protocol.
  • •9. History of renal trauma, glomerulonephritis, or patient with one kidney.
  • •10. History of malignancy (other than basal cell carcinoma or adequately treated carcinomain-situ of the cervix).
  • •11. Unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to
  • •12. Conditions assoc

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis - CAIN457A2209Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).MedDRA version: 9.1Level: LLTClassification code 10002556Term: Ankylosing spondylitis
EUCTR2008-002631-33-GBovartis Pharma Services AG30
Completed
Phase 2
Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure'Acute Heart Failure'10082206
NL-OMON46516niversitair Medisch Centrum Groningen80
Active, not recruiting
Phase 1
Randomized, double blind, placebo controlled study on the effect of the SGLT2 inhibitor (a new class of anti-diabetics with diuretic effects) Empagliflozin in patients admitted with acute decompensated heart failureAcute (decompensated) heart failureMedDRA version: 20.0Level: HLGTClassification code 10019280Term: Heart failuresSystem Organ Class: 100000004849MedDRA version: 20.0Level: HLTClassification code 10019283Term: Heart failure signs and symptomsSystem Organ Class: 100000004908MedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000011689
EUCTR2017-001679-22-NLniveristy Medical Center Groningen80
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.Duchenne Muscular Dystrophy (DMD)MedDRA version: 19.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-000401-36-ITITALFARMACO S.p.A.192
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.Duchenne Muscular Dystrophy (DMD)MedDRA version: 19.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-000401-36-ESITALFARMACO S.p.A.192
Randomized, placebo controlled, double... | Clinical Trial